the leading-edge of effective surgical prophylaxis 2017/antimicrobial surgical...- 2-5% of...
TRANSCRIPT
![Page 1: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/1.jpg)
TheLeading-EdgeofEffectiveSurgicalProphylaxis
SherylZelenitskyProfessor,CollegeofPharmacy
UniversityofManitoba
http://creativecommons.org/licenses/by-sa/4.0(WikimediaCommons)
![Page 2: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/2.jpg)
■ Ihavenocurrentorpastrela0onshipswithcommercialen00es,andwilldonatethecurrent$200speakinghonorariumtotheCSHPFounda0on.
■ Thisprogramlearningac0vityhasreceivednofinancialorin-kindsupportfromanycommercialorotherorganiza0on
Disclosures
![Page 3: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/3.jpg)
AcknowledgementsDivnaCalic,PhDcandidate
ChrisLawson,BSc(Pharm)
RyanLillico,PhDcandidate
Dr.TedLakowski,Professor
Dr.G.Zhanel,Professor
Dr.RakeshAurora,CardiacSurgery
Dr.RobAriano,Pharmacy
Dr.HilaryGrocoQ,Anesthesiology
http://cibinel.com/project/apotex-centre/
https://markosun.files.wordpress.com/2015/05/aerialspov22.jpg
![Page 4: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/4.jpg)
Outline
1. Surgicalsiteinfec0ons(SSIs)andan0microbialprophylaxis(AP)
2. Limita0onsofgold-standardtrials,meta-analyses&clinicalprac0ceguidelines
3. Whatis“effec0ve”AP?Studiesincolorectalandcardiacsurgery
4. Howtoop0mizeAPforpa0entsintheclinicalse\ng?
![Page 5: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/5.jpg)
LearningObjective
1. Tolearnhowan0microbialpharmacodynamicscontributetoeffec0vesurgicalprophylaxis;
2. Toiden0fytheprimaryvariablesinassessingan0microbialprophylaxis.
![Page 6: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/6.jpg)
- 2-5%ofsurgeries
- ↑hospitalstay7-10d,re-admission5X
- ↑mortality2-3X
- $350,000-$1millionannually
SSIhealthcareburden
KnoopKJ,StackLB,StorrowAB,ThurmanR.TheAtlasofEmergencyMedicine,4e;2016http://accessmedicine.mhmedical.com/ViewLarge.aspx?figid=125437734,AccessedFeb19,2017
https://www.swchildrens.org/Pages/health-safety/health-library/library-detail.aspx?docId=%7B0A696E96-7165-456D-AAAA-D8E2A9851EA5%7D,AccessedFeb19,2017
- 50%ofSSIsarepreventable
![Page 7: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/7.jpg)
TableII.6.7(WHO:PatientSafety:GuidelinesforSafeSurgery2009)
ü modifiablepa0entrisk-factors
ü skinprepara0on,ORinfec0oncontrol,surgicaltechnique
ü thermoregula0on,glucosecontrol,O2supplementa0on
SSIprevention
Pa0entrisk-factors:• obesity• malnutri0on• smoking• diabetes• ISmeds• coloniza0on• remoteinfec0on
Surgeryrisk-factors:• OR/surgicalcontamina0on• typeofsurgery• foreigndevice• drains• dura0onofsurgery
ü an0microbialprophylaxis
![Page 8: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/8.jpg)
- reducebacterialburdenatincisionsiteandpreventSSI
- avoidSSI-associatedmorbidity,mortality&costs
- minimizecollateralresistance(eg,MRSA,ESBL,VRE)
- avoidan0microbial-relatedadverseeffects(eg,C.difficile)
GoalsofAPareto…
![Page 9: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/9.jpg)
? selec0ngan0microbial
? selec0ngdose
? 0mingpre-opdose(within1h)
? re-dosingduringsurgery(every2t½’s)
? con0nuingajersurgery(none,<24hor48hforcardiacsurgery)
KeyAPdecisionsare…
![Page 10: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/10.jpg)
APclinicalpracticeguidelines(CPGs)
2013
![Page 11: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/11.jpg)
Limitationsofgold-standardtrials,meta-analyses&CPGs
- heterogeneouspa0ents… age,weight,Clcr,co-morbidi0es
- variablesurgeries… skinprep,ORinfec0oncontrol,dura0onofsurgery
- diverseSSIpathogens… hostnormalflora,localpathogendistribu0ons
- variousan0microbials… spectrumofac0vity,resistancerates,PKs
What is “effective” AP?
![Page 12: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/12.jpg)
APforcolorectalsurgery…
![Page 13: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/13.jpg)
Single-dose was more effective than multiple-dose gentamicin.
![Page 14: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/14.jpg)
Incision conc
AUCsurg
Closure conc
Single-dose was more effective than multiple-dose gentamicin.
![Page 15: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/15.jpg)
Gentamicin closure conc was strongest risk-factor for SSI.
![Page 16: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/16.jpg)
Critical threshold = 1.6 mg/L
Gentamicin closure conc was strongest risk-factor for SSI.
![Page 17: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/17.jpg)
APforcardiacsurgery…
![Page 18: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/18.jpg)
Image:BaronS(2013).CardiovascularTherapeutics14:214-239.
n=55,40inPDanalysis69%male65±10y(36–82y)
90±17kgClcr74±16mL/min
⇒ SSIs at 30 days
X
X
X Incision conc
Closure conc
Istherecommendedcefazolinprophylaxisadequateincardiacsurgery?
![Page 19: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/19.jpg)
₋ sex
₋ age
₋ weight
₋ BMI
₋ smoker
₋ Clcr
₋ diabetes
₋ Charlsonindex
₋ priorcardiacsurgery
₋ antibiotics<1month
₋ hospitalized<1month
₋ CABG,valvesurgery
₋ #grafts
₋ albumin
₋ glucose
₋ fluidbalance
₋ bloodreplacement
₋ CPBduration
₋ surgeryduration
₋ complications
₋ hospitalstay
₋ pre-opAPonly
₋ timingofpre-opAP
₋ cefazolindose
₋ totalcefazolindose
₋ cefazolinclosureconc
₋ cefazolinminconc
Cefazolin closure conc & duration of surgery were associated with SSI.
Zelenitskyetal.IDWeek2016,NewOrleans,NO.
Variable OR 95%CI p-value Cefazolinclosureconc(per10%decrease) 1.36 1.02-1.82 0.038
Durationofsurgery(per1hincrease) 2.94 1.13-7.64 0.027
AreaundertheROCcurve(95%CI)=0.789(0.583-0.996)Hosmer-Lemeshowp-value=0.21
![Page 20: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/20.jpg)
T50 3.9 h
T25
T75
Critical threshold = 104 mg/L
₋ sex
₋ age
₋ weight
₋ BMI
₋ smoker
₋ Clcr
₋ diabetes
₋ Charlsonindex
₋ priorcardiacsurgery
₋ antibiotics<1month
₋ hospitalized<1month
₋ CABG,valvesurgery
₋ #grafts
₋ albumin
₋ glucose
₋ fluidbalance
₋ bloodreplacement
₋ CPBduration
₋ surgeryduration
₋ complications
₋ hospitalstay
₋ pre-opAPonly
₋ timingofpre-opAP
₋ cefazolindose
₋ totalcefazolindose
₋ cefazolinclosureconc
₋ cefazolinminconc
Variable OR 95%CI p-value Cefazolinclosureconc(per10%decrease) 1.36 1.02-1.82 0.038
Durationofsurgery(per1hincrease) 2.94 1.13-7.64 0.027
AreaundertheROCcurve(95%CI)=0.789(0.583-0.996)Hosmer-Lemeshowp-value=0.21
Zelenitskyetal.IDWeek2016,NewOrleans,NO.
Cefazolin closure conc & duration of surgery were associated with SSI.
![Page 21: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/21.jpg)
“Thus,themost importantaspect inthe7minganddosingofprophylac7can7bio7csisachievingeffec7velevelsthroughoutthe7methattheincisionisopen.”
“Thus…toprovideserumand7ssueconcsexceedingtheMICsformostprobableorganisms…atthe7meof incision,andforthedura7onoftheprocedure.”
What is “effective” AP?
![Page 22: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/22.jpg)
How can this optimize AP for patients in the clinical setting?
![Page 23: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/23.jpg)
Bratzleretal.AmJHealth-SystPharm2013;70:195-283.
![Page 24: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/24.jpg)
30 40 50 60 70 80 90AGE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0 50 100 150WT
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
Proportion per B
ar
0
100
200
300
400
500
600
700
800C
ount
50 60 70 80 90 100 110 120 130CLCR
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20VDL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
0 5 10 15 20 25VD
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
Proportion per B
ar
0
100
200
300
400
500
600
700
Cou
nt
1.0 1.5 2.0 2.5 3.0T12
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
0.2 0.3 0.4 0.5KE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
1 2 3 4 5 6 7 8 9CL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10CLKG
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20F
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
100 200 300 400FD
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
10 20 30 40 50 60 70CP
0.00
0.02
0.04
0.06
0.08
0.10
0.12
Proportion per B
ar0
100
200
300
400
500
600
Cou
nt
30 40 50 60 70 80 90AGE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0 50 100 150WT
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
Proportion per B
ar
0
100
200
300
400
500
600
700
800
Cou
nt
50 60 70 80 90 100 110 120 130CLCR
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20VDL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
0 5 10 15 20 25VD
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
Proportion per B
ar
0
100
200
300
400
500
600
700
Cou
nt
1.0 1.5 2.0 2.5 3.0T12
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
0.2 0.3 0.4 0.5KE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
1 2 3 4 5 6 7 8 9CL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10CLKG
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20F
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
100 200 300 400FD
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
10 20 30 40 50 60 70CP
0.00
0.02
0.04
0.06
0.08
0.10
0.12
Proportion per B
ar
0
100
200
300
400
500
600
Cou
nt
30 40 50 60 70 80 90AGE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0 50 100 150WT
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
Proportion per B
ar
0
100
200
300
400
500
600
700
800
Cou
nt
50 60 70 80 90 100 110 120 130CLCR
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20VDL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
0 5 10 15 20 25VD
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
Proportion per B
ar
0
100
200
300
400
500
600
700
Cou
nt
1.0 1.5 2.0 2.5 3.0T12
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
0.2 0.3 0.4 0.5KE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
1 2 3 4 5 6 7 8 9CL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10
CLKG
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20F
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
100 200 300 400FD
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
10 20 30 40 50 60 70CP
0.00
0.02
0.04
0.06
0.08
0.10
0.12
Proportion per B
ar
0
100
200
300
400
500
600
Cou
nt
E.coli32%
MSSA15%
MRSA4%
P.aeruginosa10%
Klebsiellaspp9%
Streptococcusspp9%
S.epidermidis9%
Enterobacterspp8%
Proteusspp4%
30 40 50 60 70 80 90AGE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0 50 100 150WT
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
Proportion per B
ar
0
100
200
300
400
500
600
700
800
Cou
nt
50 60 70 80 90 100 110 120 130CLCR
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20VDL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
0 5 10 15 20 25VD
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
Proportion per B
ar
0
100
200
300
400
500
600
700
Cou
nt
1.0 1.5 2.0 2.5 3.0T12
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar0
100
200
300
400
Cou
nt
0.2 0.3 0.4 0.5KE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
1 2 3 4 5 6 7 8 9CL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10CLKG
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20F
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
100 200 300 400FD
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
10 20 30 40 50 60 70CP
0.00
0.02
0.04
0.06
0.08
0.10
0.12
Proportion per B
ar
0
100
200
300
400
500
600
Cou
nt
30 40 50 60 70 80 90AGE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0 50 100 150WT
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
Proportion per B
ar
0
100
200
300
400
500
600
700
800
Cou
nt
50 60 70 80 90 100 110 120 130CLCR
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20VDL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
0 5 10 15 20 25VD
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
Proportion per B
ar
0
100
200
300
400
500
600
700
Cou
nt
1.0 1.5 2.0 2.5 3.0T12
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
0.2 0.3 0.4 0.5KE
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
1 2 3 4 5 6 7 8 9CL
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.10CLKG
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
Proportion per B
ar
0
100
200
300
400
500
Cou
nt
0.05 0.10 0.15 0.20F
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
100 200 300 400FD
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
Proportion per B
ar
0
100
200
300
400
Cou
nt
10 20 30 40 50 60 70CP
0.00
0.02
0.04
0.06
0.08
0.10
0.12
Proportion per B
ar
0
100
200
300
400
500
600
Cou
nt
%ofcaseswhereAPcoversprobableSSIpathogens
duringsurgery
MCSn=5,000
Pa0entdemographics–age,wt,Clcr An0microbialPKs–Vd,t½,%free
SSIpathogen,MICdistribu0onsSurgerydura0on
Zelenitskyetal.JAC2016;;71:2902-8.
MonteCarlosimulation(MCS)modelling
![Page 25: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/25.jpg)
Zelenitskyetal.JAC2016;71:2902-8.
Ertapenem1g
Cejriaxone2gGentamicin5mg/kgLevofloxacin500mg
Cefazolin2gCefoxi0n2g
%ofcaseswhereAPcoversallprobableaerobicSSIpathogens
![Page 26: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/26.jpg)
Metronidazole500mgErtapenem1g
Clindamycin900mgCefoxi0n2g
Zelenitskyetal.JAC2016;71:2902-8.
%ofcaseswhereAPcoversallprobableanerobicSSIpathogens
![Page 27: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/27.jpg)
5mg/kg
S.aureusOtherEnterobacteriaceaeE.coliAllSSIaerobes
3mg/kg 1.5mg/kg
Zelenitskyetal.JAC2016;;71:2902-8.
%ofcaseswheregentamicincoversallprobableaerobicSSIpathogens
![Page 28: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/28.jpg)
OtherAPquestions…
“Thus, themost important… is achieving effec7ve levels throughout the7methattheincisionisopen.”(WHOGlobalguidelinesforthepreven0onofSSI2016)
? selec0ngan0microbial
? selec0ngdose
? 0mingpre-opdose
? re-dosingduringsurgery
? con0nuingajersurgery
- Whentousecejriaxoneinsteadofcefazolinincolorectalsurgery?- ShouldazithromycinbeaddedtocefazolininC-sec0ons?(Titaetal,NEJM2016)
- Howtodosecefazolininobesepa0entsie,3gfor>120kg?
Today’s Hospital 2005 – “Why timing is everything with AP and surgery” Medscape ID 2013 – “Surgical AP: Timing doesn’t alter risk”
- Howtoconsiderrenalfunc0oninre-dosing?- Shouldcon0nuousinfusioncefazolinbeusedincardiacsurgery?
![Page 29: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/29.jpg)
Selectreferences(recentprac0ceguidelines,reviewsandresources):
§ Andersonetal.Strategiestopreventsurgicalsiteinfec0onsinacutecarehospitals:2014update.InfectControlHospEpidem2014;34(6):605.
§ Banetal.AmericanCollegeofSurgeonsandSurgicalInfec0onSociety:Surgicalsiteinfec0onguidelines,2016update.JAmCollSurg2017;224(1):59.
§ Bratzleretal.Clinicalprac0ceguidelinesforan0microbialprophylaxisinsurgery.AmJHealth-SystPharm2013;70(3);195.
§ Bronwenetal.Surgicalsiteinfec0ons:anupdate.InfectDisClinNAm2016;30:909.
§ CanadianPa0entSafetyIns0tute:SurgicalSiteInfec0ons(Ge\ngStartedKit)(hQp://www.pa0entsafetyins0tute.ca/en/Topic/Pages/Surgical-Site-Infec0on-(SSI).aspx);(hQp://www.pa0entsafetyins0tute.ca/en/toolsresources/pages/ssi-resources-ge\ng-started-kit.aspx)
§ Najjaretal.Prophylac0can0bio0csandpreven0onofsurgicalsiteinfec0ons.SurgClinNAm2015;95:269.
§ WHOGlobalguidelinesforthepreven0onofsurgicalsiteinfec0on2016(hQp://www.who.int/gpsc/ssi-guidelines/en/)
§ WHOGuidelinesforSafeSurgery2009.(hQp://www.who.int/pa0entsafety/safesurgery/tools_resources/9789241598552/en/)
![Page 30: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/30.jpg)
Thankyou!Questions?
![Page 31: The Leading-Edge of Effective Surgical Prophylaxis 2017/Antimicrobial Surgical...- 2-5% of surgeries - ↑ hospital stay 7-10 d, re-admission 5 X - ↑ mortality 2-3 X - $350,000-$1](https://reader035.vdocuments.site/reader035/viewer/2022071219/6056e7e4559d1f2282027084/html5/thumbnails/31.jpg)